Bioxytran, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIXT research report →
About the company
Bioxytran, Inc. is a pharmaceutical firm operating in the clinical development phase, dedicated to creating, producing, and marketing medicinal treatments for oxygen deficiency (hypoxia) in people. Its primary drug under development, BXT-25, is a small, oxygen-transporting molecule crafted from bovine hemoglobin, stabilized by a co-polymer.
- CEO
- David Platt
- IPO
- 2010
- Employees
- 3
- HQ
- Newton, MA, US
Price Chart
- Market Cap
- $2.84M
- P/E
- -0.98
- P/S
- 0.00
- P/B
- -0.64
- EV/EBITDA
- -1.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 90.64%
- ROIC
- 102.75%
- Revenue
- $0 · 0.00%
- Net Income
- $-2,123,077 · 10.29%
- EPS
- $-0.02 · -35.09%
- Op Income
- $-1,854,053
- FCF YoY
- -527.24%
- 52W High
- $0.10
- 52W Low
- $0.02
- 50D MA
- $0.03
- 200D MA
- $0.05
- Beta
- 1.82
- Avg Volume
- 64.92K
Get TickerSpark's AI analysis on BIXT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 25 | Hoberman Alan M | other | 38,588 |
| Aug 12, 25 | Hoberman Alan M | other | 10,417 |
| Nov 18, 25 | Hoberman Alan M | buy | 210,000 |
| Nov 14, 25 | MILANOVA RADKA | other | 38,588 |
| Aug 12, 25 | MILANOVA RADKA | other | 10,417 |
| Nov 14, 25 | CONAWAY DALE H | other | 38,588 |
| Aug 12, 25 | CONAWAY DALE H | other | 10,417 |
| Nov 14, 25 | Utter Anders | other | 38,588 |
| Oct 24, 24 | PLATT DAVID | other | 11,433,448 |
| Oct 24, 24 | PLATT DAVID | other | 14,085,410 |
Our BIXT coverage
Recent articles, reports, and earnings notes.
No research on BIXT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIXT report →Similar companies
Peers in the same neighborhood.